



ELSEVIER
SAUNDERS

Psychiatr Clin N Am
28 (2005) 1093–1121

PSYCHIATRIC
CLINICS
OF NORTH AMERICA

Cumulative Index 2005

Note: Page numbers of article titles are in **boldface** type.

A

- Abetalipoproteinemia, 284–285
- Absence seizures, frontal lobe, and spike wave stupor, 641–642
- Acamprosate, in alcohol dependence, 904
- Activities interventions, for dementia-related behavioral symptoms, in nursing home residents, 993, 995–996, 998
- Acupuncture, in neuropathic pain, 731
- Acutely violent patient. *See also Violence*, management of, **701–711**
- Addiction. *See also Nicotine addiction; Psychostimulant abuse*, animal models of, 741–742 defined, 737 neuroanatomic and neurotransmitter correlates of, 742
- Adherence to prophylactic treatment, in bipolar disorder, 372–373
- Adolescents, bipolar disorder in, atypical antipsychotics in, 391–393 diagnosis of, 386–387 incidence of, 385–386 pharmacotherapy of, 388–394 substance use disorder and, 388 treatment strategies in, 393–394 depression in, obesity and, 45 low-glycemic index diets in, studies of, 133–134 obesity in, health risks of, 14–15
- Affect, conceptual formulations of, 538 emotional circuitry in, 540
- Affective disorders, in Huntington's disease, 180
- Affective illnesses, gene-environment interaction in, 490
- Aggressive behavior, 703
- Aging, normal, memory disorders in, impairment of retrieval processes, 591
- Agitation, in dementia syndromes, 985–986 antipsychotics for, 943–949, 963–965 manifestation of, 985 signs and symptoms of, 704 verbal de-escalation of, 707–708 violent outcomes of, 704
- Agnosia(s), algorithms for, 534–536 apperceptive, 529–530 associative, 530 auditory, 534, 536 conceptual foundations of, 529–530 tactile, 536 visual, 530, 533, 535
- Agouti-related protein (AgRP), in energy balance regulation, 28–30, 29–30
- Akathisia, acute neuroleptic-induced, aspects of, 257 causes of, 257 characterization of, 257–258 diagnosis of, 257–258 pharmacologic treatment of, 259
- Alcohol abuse, in bipolar disorder, prevalence of, 416 in elderly patient, evidence-based research on, summary of, 906–907 in major depressive disorder, 416 in mania, 417
- Alcohol dependence, definition of, 898 in elderly patient, prevalence of, 899
- Alcohol withdrawal, in elderly patient, symptoms of, 904
- Alpha-melanocyte-stimulating hormone, in energy balance regulation, 28
- Alzheimer, A., 507

- Alzheimer's disease (AD), anterograde episodic memory impairment in, 591
- Amino acid neurotransmitters, on proton magnetic resonance spectroscopy, in bipolar disorder, 452
- Amnesia, search for an animal model for, 607-608
- Amnesic syndrome(s), 526, 527
Korsakoff syndrome, 592-593
medial temporal lobe amnesia, 599-611
- Amphetamine addiction, need for new therapies, 740-741
psychiatric disorders coexisting in, 740
- Amygdala, in memory, 588
on structural magnetic resonance imaging, in bipolar disorder, 446-447
- Analgesia, in neuropathic pain, narcotic, 728-730
topical, 729
- Anosognosia, 540
- Anticholinergics, memory impairment from, 594
movement disorders and, 255
- Anticonvulsants, for dementia-related behavioral symptoms, in nursing home residents, 990-991
in elderly/older patients, efficacy of, 850-851
side effects of, 842-843, 845-848
- Anticonvulsant(s), in bipolar depression, 354-356
in bipolar disorder, 301-323
 carbamazepine, 306-308
 cognitive function and, 435
 efficacy of, comparative, 319-320
 gabapentin, 314-316
 lamotrigine, 309-313
 levetiracetam, 317
 oxcarbazepine, 308-309
 pharmacologic profiles of, 303
 phenytoin, 317-319
 topiramate, 313-314
 valproate or divalproex sodium, 302-306
 zonisamide, 316-317
in neuropathic pain, 727
movement disorders with, 255
- Antidepressants, for dementia-related behavioral symptoms, in nursing home residents, 989, 991-992
- in Alzheimer's disease, vascular dementia, and mixed dementia, 955-957, 967-968
in antipsychotic augmentation, in schizophrenia, 926-929, 933
in bipolar depression, 351-353
 continuation of, 361-363
 depression and, 362-363
 hypomania and, 362
 effectiveness of, 351-353
in elderly/older patients, side effects of, 848, 854
in generalized anxiety disorder, 890
in neuropathic pain, 728
in panic disorder, 890
mania and rapid cycling and, 358-361
weight gain with, 50-51
 monitoring for, 51
- Antiepileptics, in bipolar disorder, in children and adolescents, 390-391
in frontal lobe seizures, 648-649
in nonconvulsive status epilepticus, 661
- Antipsychotics. See also *Atypical antipsychotic(s)*.
diabetes mellitus, type 2, and dyslipidemia and, 49
risk for, 49
for dementia-related behavioral symptoms, in nursing home residents, 987-989, 991, 999
in Alzheimer's disease, vascular dementia, and mixed dementia, treatment recommendations, 975-977
in Alzheimer's disease, vascular dementia, mixed dementia, efficacy of, 970
in elderly/older patients, efficacy of, 851-852
 side effects of, 846-847
in Parkinson's disease with psychosis, 958-960, 968-969
in psychosis and agitation, of Alzheimer's disease, vascular dementia, and mixed dementia, 943-949, 963-965
in schizophrenia, in older adults, 916-926, 931-935
movement disorders with, 47
obesity and, 47-50
weight gain with, 47-48
 monitoring for, 49-50
- Anton's syndrome, 540-541
- Anxiety, in chronic pain, 718-719

- in late life, benzodiazepines for, 889-890
pharmacologic treatments for, 889-890
- Anxiety disorders, binge eating disorder and, 108-109
comorbid with bipolar disorder, 373
familial aggregation in, 489
in Huntington's disease, 180
in late life. See also *Geriatric anxiety disorders*.
evidence-based treatment of, **871-896**
impact of, 872-873
prevalence of, 871-872
mixed, cognitive behavioral interventions for, in elderly patient, 887-888
- Apathy, in Huntington's disease, 279-280
- Aphasia(s), Broca's, 518
conduction, 521
in cerebral white matter disorders, 694-695
transcortical motor, 519
transcortical sensory, 520
Wernicke's, 520
- Aripiprazole, in bipolar disorder, for continuation and maintenance therapy, 343-344
- Arousal, clinical terminology in, 512
in neuropsychiatric assessment, assessment of, 512, 517-518
- Assaults, on psychiatrists and psychiatric residents, 701
- Assosiation studies, 482
in bipolar disorder, brain-derived neurotrophic factor, 486-487
G72/G30, 486
methodologic issues in, 485-486
monoamine oxidase A, 487-488
serotonin transporter gene, 5-HTT, 475
- Astereognosia, 530
- Attention, assessment tasks in, 515, 521
conceptual foundations of, 519-521
deficits in, 577, 697
in cerebral white matter dementia, 694
impaired, in schizophrenia, 615-616
in neuropsychiatric assessment, 514, 515
- Attentional syndromes, 515
- Attention/concentration, in bipolar disorder, 427-428
- Attention deficit disorder (ADD), prefrontal dysfunction in, 577
- Attention deficit/hyperactivity disorder (ADHD), co-occurrence with bipolar disorder, in children, 387
combination therapy for, 393-394
white matter abnormalities in, 697
- Atypical antipsychotic(s), cerebrovascular adverse events with, 972-974
clozapine as prototype, 325
in acute bipolar depression, olanzapine in, 336-337
quetiapine, 337
in acute mania, as acute monotherapy vs. mood stabilizers or conventional antipsychotics, 334-335
combination therapy studies, 333, 336
depressive symptom induction in, 332-333
double-blind active comparator studies of, 333
placebo-controlled monotherapy studies, 326-329
onset of action in, 330
patient subgroups in, 332
primary efficacy measure in, 330
remission rates in, 331-332
response rates in, 330-331
- in Alzheimer's disease, vascular dementia, and mixed dementia, 954-965
safety and tolerability of, 972-975
- in Alzheimer's disease, vascular dementia, mixed dementia, efficacy of, 970
- in bipolar depression, 364-365
olanzapine, 356-357
- in bipolar disorder, **325-347**
as adjunct to mood stabilizers vs. mood stabilizer monotherapy, 338-339
clinical trials and, 325-326
cognitive function and, 435
combination therapy, in children and adolescents, 393
for continuation and maintenance therapy, 337-344

- Atypical antipsychotic(s) (*continued*)
 in children and adolescents,
 391-393
 dosing/monitoring of, 392
 neuroprotective effect of, 435
 properties of, 326
 studies as acute monotherapy vs.
 placebo, 327-329
 in continuation and maintenance
 therapy, aripiprazole, 340-341
 vs. haloperidol, 343-344
 double-blind active comparator
 monotherapy studies, 341
 olanzapine, 340
 vs. divalproex sodium,
 342-343
 vs. haloperidol, 343
 vs. lithium, 342
 placebo-controlled monotherapy
 studies, 340
 quetiapine, vs. haloperidol, 344
 vs. lithium, 344
 vs. placebo vs. haloperidol,
 341
 vs. placebo vs. lithium, 341
 risperidone vs. haloperidol, 343
 in dementia, treatment
 recommendations, 976-978
 in smoking cessation, 739
 metabolic abnormalities with, 48
 side effects of, 392
 weight gain with, 47-48
- Aura, in bizarre hyperactive seizures, 638
 in frontal lobe seizures, 637-638
- Awareness, assessment criteria for, 513,
 518

B

- Bariatric surgery, body image and,
 improvement of, 81
 candidates for, 170-171
 development of, 220
 effects on comorbid conditions in
 metabolic syndrome, 229-232
 indications and evaluation for, 220
 laparoscopy and, 228
 malabsorptive procedures, 223
 biliopancreatic diversion (with
 and without duodenal
 switch), 223-224
 restrictive procedures, adjustable
 gastric band, 226-228
 gastric bypass, 225
 vertical banded gastroplasty,
 225-226, 228
 Roux en Y gastric bypass, 220-223,
 226
- Basal forebrain, in memory, 589-590
- Basal ganglia, in structural magnetic
 resonance imaging, in bipolar disorder,
 447
- Behavioral disturbances, improvement in, in
 home- and community-based care,
 1053
- Behavioral sensitization, from nicotine and
 psychostimulant exposure, 741
- Behavioral symptoms, dementia-related.
*See Dementia-related behavioral
 symptoms, in nursing home residents.*
- Behavioral therapy, for late-life depression,
 810
- Behavioral treatment, of obesity,
 characteristics of, goal-orientation,
 153
 process orientation, 153
 small versus large changes,
 153-154
 cognitive restructuring in, 155
 group versus individual, 156-157
 long-term results of, 160-162
 with telephone and mail
 contact, 161
 practice of key behaviors in,
 162-163
 principles of, 152-153
 self-monitoring in, 154
 short-term weight loss with, 157
 dietary option with,
 158-160
 stimulus control in, 154-155
 structure of, 155-156
 summary of studies, 157
 with Internet and e-mail,
 161-162
- Behavioral weight loss programs, in binge
 eating disorder, 59
- Benzodiazepines, adjunctive, in bipolar
 disorder, 847-848
 in agitation, 709
 in generalized anxiety disorder,
 889-890
 in late life, 889-890
 in nonconvulsive status epilepticus,
 661
 memory deficits from, 593
- Benzphetamine, in obesity, 196
- Binge eating disorder, behavioral weight
 loss programs for, 59
 diagnostic features of, 55-56
 obesity and, 55-60, 108-110
 placebo responsiveness of, 58-59

- prevalence of, 56
psychiatric comorbidity in, 56-57
psychopharmacologic treatment of, 57-58
psychotherapy for, 57
risk factors for, 56-57
variability of, 59-60
- Bipolar depression**
anticonvulsants in, 354-356
 bupropion, 356, 365
 gabapentin, 356
 lamotrigine, 354-356
 topiramate, 356
 zonisamide, 356
antidepressants in, chart review of, 352-353
 SSRIs, 351-352
 SSRIs with mood stabilizers, 352
 stimulants, 351
 suicide and, 353
 tricyclics, 351-352
 with lithium, 351
atypical antipsychotics in, 356-357
 carbamazepine in, 307
 characterization of, 350
 co-occurrence with substance use disorder, 349
 dopamine agonists for, 357-358
 electroconvulsive therapy for, 357
 in children and adolescents, treatment of, 394
 lamotrigine in, 310
 lithium in, antidepressant effect of, 353-354
 mifepristone (RU-486) in, 358
 olanzapine in, studies of, 336-337
 oxcarbazepine in, 309
 quetiapine in, studies of, 337
 topiramate in, 313-314
 treatment of, **349-370**
 algorithm for, 364
 atypical antipsychotics in, 364-365
 mood stabilizers in, 363, 365
 nonpharmacologic, 365
 recommendations for, 363-366
 valproate/divalproex sodium in, 304-305
 with hypomanic symptoms, 351
 with psychotic symptoms, 351
- Bipolar disorder, atypical antipsychotics in**
continuation and maintenance therapy, 337-344
characterization of, 427
genetics in. *See Genetics, in bipolar disorder.*
geriatric, pharmacological treatment of, **837-869**
gray matter in, 406-408
in children. *See Children, bipolar disorder in.*
in elderly/older patients,
 anticonvulsants for, 842-843, 845-848
 antidepressants for, 848
 antipsychotics for, 846-847
 benzodiazepines for, adjunctive, 847-848
 lithium for, 839-845
 pharmacological treatment of, efficacy of, 850-856
 in continuation/
 maintenance therapy, 856-859
 pharmacodynamic
 modifiers of toxicity and, 848-850
 side effects of, 839-844
obesity and, 46
overweight and obesity risk with, 52
psychologic treatments in. *See also Psychologic treatments,*
 rationale for, 372-373
 studies of, 374-380
psychosocial therapies for, historical perspective on, 371-372
treatment of, prophylactic, 491
white matter abnormalities in, 697
- Bipolar II disorder, familial aggregation in**, 489
- Bizarre hyperactive seizures (hypermotor or complex partial seizures of frontal lobe origin)**, 638-640
clinical manifestations of, 638-640
- BMI (body mass index)**, in obesity, 2, 113
in overweight, 1-2
- Body dysmorphic disorder**, 72
- Body image, and obesity, 69-87**
assessment in obese adults, 73-80
 appearance satisfaction measures in, 78
 body image investment measures in, 78-79
Body Image Quality of Life Inventory, 76-78
gender and ethnicity
 considerations in, 79-80
Multi-dimensional Body Self-Relations Questionnaire in, 73, 78, 79
schematic figure rating
 methodologies in, 74, 78
shape satisfaction in, 79
Situational Inventory of Body Image Dysphoria in, 78

- Body image, and obesity (*continued*)
size perception measures in, 79
weight satisfaction measures in,
74-78
improvements in, with bariatric
surgery, 81
without weight loss, 81-82
with weight loss, 80-81
- Body image dissatisfaction, behavioral
effects of, 71
body dysmorphic disorder and, 72
child-onset obesity and, 71
clinical significance of, 71-72
in obese adults, treatment of, 80-82
in overweight and obese women,
70-71
motivation for weight loss and,
72-73
nature of, 70-71
prevalence of, 69-70
variation across groups, 70
treatment of, with and without weight
loss, 80-82
- Body mass index (BMI). See *BMI (body
mass index)*.
- Body representation, 525, 529
- Brain, in bipolar disorder, neuroanatomic
correlates of cognition and, 436
structural abnormalities in,
437-438
lobes of, in neuropsychologic
evaluation, 431
- Brain-derived neurotrophic factor (BDNF),
in bipolar disorder, association studies,
486-487
- Brainstem, in structural magnetic resonance
imaging, in bipolar disorder, 448
- Brain volumes, in structural magnetic
resonance imaging, in bipolar disorder,
444
- Brief psychodynamic therapy, for late-life
depression, 813-814
- Bupropion, in bipolar depression, 356, 365
in weight loss, 51, 201
mania with, 360-361
- Buspiron, for dementia-related behavioral
symptoms, in nursing home residents,
990
- C**
- California Verbal Learning Test, of working
memory, 577
- Cancer, obesity and, 14
- Capgras syndrome, in delusional
misidentification, 666-667
in schizophrenia, 666
- Carbamazepine, dosage and serum-level
monitoring of, 307
for dementia-related behavioral
symptoms, in nursing home
residents, 990-991
in acute mania, 306-307
in Alzheimer's disease, 954
in bipolar depression, 307, 363
in bipolar disorder, in children and
adolescents, 390
with cocaine dependence,
420-421
in elderly/older patients,
considerations in, 860
efficacy of, 851
side effects of, 849
maintenance efficacy of, 307
tolerability of, 307-308
- Caregiver interventions, for caregivers of
older adults with late-life mood
disorder, 1028-1029
for dementia caregivers, 1010-1023,
1029
for stroke caregivers, 1011,
1024-1029
in geriatric psychiatry, **1007-1038**
limitations of recent studies,
assessment procedures,
1030
implementation and
reception by
participants, 1030
methodological problems,
1029-1030
outcome assessment and,
1031
study method and results,
1009-1010
summary of literature reviews,
1008-1009
- Caregiver training, for home-care of elderly,
1045
- Catechol-O-methyltransferase, in bipolar
disorder, association studies, 488
- Cerebellum and vermis, in structural
magnetic resonance imaging, in
bipolar disorder, 448
- Cerebral white matter, anatomy and
physiology of, 686-687
background of, 685-686
behavioral neurology of, 697
disorders of, 689-691
classification of, 689-690

- cognitive dysfunction in,
692-694
dementia, 692-694
focal neurobehavioral
syndromes, 694-695
gene therapy and, 692
immunomodulation and, 692
neurobehavioral aspects of,
685-700
neuropsychiatric syndromes in,
696-697
prevention of, 692
prognosis for, 691-692
in development and aging, 687-688
neuroimaging of, 688-689
- Children, bipolar disorder in, atypical
antipsychotics in, 391-393
comorbid disorders with,
387-388
diagnosis of, 386-387
mood stabilizers in, 388-391
pharmacotherapy of, 388-394
treatment strategies in, 393-394
low-glycemic index diets in, studies of,
132-134
mania in, confounders mimicking,
387
obesity in, 14-15, 242-243, 245-248
health risks of, 14-15
prevalence of, 7, 9-10
prevention of, food in schools
and, 242-243
physical activity in schools
and, 245-248
- Chlorpromazine, in schizophrenia in older
adults, 916, 918, 932-933
- Cholecystokinin (CCK), food intake
reduction and, 205
- Choline-containing compounds, on proton
magnetic resonance spectroscopy, in
bipolar disorder, 451
- Cholinesterase inhibitors, for dementia with
Lewy bodies, treatment
recommendations, 978
in dementias, 966
efficacy of, 970-971
in dementia with Lewy bodies, 969,
971
in Parkinson's disease, 968
- Chorea. See also *Huntington's disease*,
differential diagnosis of, 275
tests used in evaluation of, 276
- Chorea-acanthocytosis, 284
- Chronic pain, 713-735. See also
Neuropathic pain; *Pain*.
- Ciliary neurotrophic factor (axokine),
weight reduction with, 204-205
- Citalopram, for dementia-related
behavioral symptoms, in nursing home
residents, 989, 991-992
in Alzheimer's disease, vascular
dementia, and mixed dementia,
955-956, 968
in schizophrenia in older adults, in
antipsychotic augmentation,
828, 927
- Clonic seizures, focal, frontal lobe, 640
- Clozapine, in Parkinson's disease, 978
efficacy of, 971-972
safety and tolerability of, 975
in Parkinson's disease with psychosis,
958-960, 968
in schizophrenia in older adults, 918,
921, 932-933
prototypal atypical antipsychotic, 325
reduction in smoking with, 739
- Cocaine abuse, in bipolar depression, 417
need for new therapies, 740-741
- Cognition, comparison of in bipolar
disorder and schizophrenia, 437
in bipolar disorder, 427-441
age and, 433
deficits in, 475
dysfunctional, 432
factors influencing, 433-434
in euthymic disorder, 433
medications affecting, 434-435
neuroanatomic correlates of,
436
psychosocial functioning and,
434
research in, methodologic issues
in, 435-436
severity/chronicity and, 433-434
in schizophrenia, areas of impairment
in, 615-622
- Cognitive behavioral social skills training
(CBSST), in schizophrenia in older
adults, 926, 928-930
- Cognitive behavioral therapy, in bipolar
disorder, 366, 422
in chronic pain patient, 716
in substance use disorder, 422
- Cognitive behavioral therapy (CBT), in
anxiety disorder, mixed, in elderly
patient, 887-888
in dysthymia, late-life, 811-812
in generalized anxiety disorder, in
elderly patient, 873-879,
884-886

- Cognitive behavioral (*continued*)
 in late-life depression, 810-811
 in major depression, late life, 810-811
 in obsessive-compulsive disorder, in elderly patient, 886-887
 in panic disorder, in elderly patient, 886
- Cognitive Bias Task (CBT), in Executive Control Battery, 574-575
- Cognitive dysfunction, medication-related, 593
- Cognitive enhancing agents, efficacy of, 977
 in Alzheimer's disease, vascular dementia, and mixed dementia, 950-952, 965-966
 in Parkinson's disease and dementia with Lewy bodies, 961-962, 969
- Cognitive impairment, in schizophrenia-spectrum disorders, 431-432
 mild, memory disorders in, 591-592
- Cognitive therapy, in bipolar disorder, 373, 374-375, 377-379
- Cognitive trait markers, in bipolar disorder, 436-437
- Community-based mental health services, evidence-based study of, discussion of, 1043, 1056-1058
 method in, 1041-1042
 results in, 1042-1043
- Community-based treatment, of late-life mental illness, evaluation studies of, 1044-1047
 outcomes of quasi-experimental and uncontrolled cohort studies, 1052-1055
 outcomes of randomized controlled trials, 1048-1051
- Competing Programs Test, in Executive Control Battery, 572
- Complex regional pain syndrome, 718
- Computed tomography (CT). See *CT (computed tomography)*.
- Conduct disorder, in children with bipolar disorder, 387-388
- Confabulation, bilateral frontal deficits and, 675-676
 definition of, 673
 delusional misidentification and, 673-675
 dissociation from, 674-675
 right hemisphere pathology and, 675
 theories of, 673-674
 ventromedial frontal damage and, 675
- Consciousness, in frontal lobe seizures, 637
- Coronary artery disease, obesity and, 12-13
- Corpus callosum, in structural magnetic resonance imaging, in bipolar disorder, 449
- Corticosteroid injections, epidural, in neuropathic pain, 730
- Corticotrophin-releasing hormone (CRH) antagonists, in HPS dysfunction and mood disorders, 476
- Cortisol, abnormalities of, in depression, 471
 and bipolar disorder, 472-474
 central and peripheral effects of, 470
 concentrations in bipolar vs. unipolar patients, 473
 function in mania, 473
 high levels of and reduced GR function, effects of, 475
 mediation of, by glucocorticoid receptor, 470-471
 by mineralocorticoid receptor, 470-471
- CT (computed tomography), attenuation values and appearance of nervous system tissues, 551-552
 description of, 550-551
 disadvantages of, 551
 enhanced axial image, 551
 unenhanced axial image, 550
 volumetric, in brain imaging, 555
 X-ray beam attenuation in, 550
-
- D**
- Decision making, actor-centered, prefrontal cortex in, 574
 vs. veridical, mechanisms in, 573
- Delis-Kaplan Executive Function System (D-KEFS), in executive control evaluation, 570
 independent tests in, 571
- Delusional misidentification, **665-683**
 and brain pathology, 666-668
 and the self, 677-678
 Capgras-type, and brain pathology, 666-667

- asomatognosia, 667
 - case review of, 669-670
 - ego function disturbance and, 676-677
 - explanations for, 671-676. See also *Confabulation*.
 - anatomic disconnection, 671-673
 - memory, executive impairment, and confabulation, 673-677
 - spatial disorientation, 671
 - features of, 670-671
 - Frégoli-type, 667-668
 - motivation in, 676
 - pharmacotherapy for, 678
 - reduplication without misidentification, 668
- Delusional misidentification syndrome (DMS), Capgras-type, 665-666
 - Frégoli-type, 665-666
 - medical comorbidities with, 666
- Dementia-related behavioral symptoms, in nursing home residents, activities interventions for, 993, 995-996, 998
 - anticonvulsants for, 990-991
 - antidepressants for, 989, 991-992
 - antipsychotics for, 987-989, 991, 999
 - evidence-based interventions for, **985-1006**
 - pharmacologic interventions for, 987-992, 998-999
 - sensory therapy for, 997-998
 - training interventions for, 991-995, 999-1000
- Dementia(s), cerebral white matter, 692-694
 - deficits in, 694
 - vs. cortical and subcortical dementias, 694
 - frontal lobe, memory dysfunction in, 592
 - functional MRI in, 557
 - in spinocerebellar ataxias, 282
- Dementia with Lewy bodies (DLB), antipsychotics for, efficacy of, 971-972
 - cholinesterase inhibitors for, 971, 978
 - pharmacological interventions in, 975
- Depression, animal models of, 403-404
 - binge eating disorder and, 108-109
 - bipolar. See *Bipolar depression*.
 - body image dissatisfaction and, 71-72
 - care management in, mental health specialist in, 1069-1070
 - collaborative care in, 1061-1062
 - executive deficit and memory impairment in, 578
 - geriatric. See *Geriatric depression*.
 - improvement in, in home- and community-based care, 1052
 - in chronic pain, 718
 - in extremely obese persons, 42-43
 - mechanisms in, 43-44
 - in Huntington's disease, 279
 - integrated management in primary care, **1061-1077**
 - cost effectiveness of, 1074
 - gaps in knowledge and service delivery in, 1073-1074
 - improving mood: promoting access to collaborative treatment, 1063-1066, 1070
 - multisite studies of, design of, 1063
 - implications for clinical practice, 1072-1073
 - intervention in, 1064
 - prevention of suicide in primary care elderly: collaborative trial, 1063-1064, 1067, 1070-1071
 - primary care research in substance abuse and mental health for the elderly trial, 1062-1065
 - re-engineering systems for primary care treatment of depression, 1063-1064, 1068-1069
 - loss of appetite and weight in, 46
 - night eating syndrome and, 60-61
 - obesity and, 40-41, 108
 - gender differences in, 41-42
 - health-related quality of life and, 43-44
 - temporal relationship in, 44-45
 - psychotic, in elderly patient, 829
 - short-term memory dysfunction in, 593
 - weight gain and, 45-46
- Dexamethasone/corticotropin-releasing hormone (DEX/CRH) challenge test, 471
 - abnormalities in, 473
- Dexamethasone (DEX) suppression test, 471
- d-Fenfluramine, in binge eating disorder, 58

- Diabetes mellitus, type 2, and impaired glucose tolerance, obesity and, 9-10
risk for, with antipsychotic medications, 49
weight loss for, Look AHEAD study of, 166
- Diabetes Prevention Program, lifestyle intervention in, 151
- Diazepam, for dementia-related behavioral symptoms, in nursing home residents, 989
- Diethylpropion, in obesity, 196
- Diet(s), high-protein, 128-129
high-protein, low-carbohydrate, with behavioral treatment, 159-160
low-carbohydrate, 130-131
low-fat, 124-126
low-glycemic index, 132-134
macronutrients and. See also *Macronutrient(s)*.
in weight regulation, 118-121
moderate-fat, 125, 127-128
portion-controlled, with behavioral treatment, 159
very-low calorie, portion-controlled, 158
very low-fat, 126-127
- Disconnection syndromes, 532, 534
- Divalproex, for dementia-related behavioral symptoms, in nursing home residents, 990-991
in Alzheimer's disease, vascular dementia, and mixed dementia, 953-954, 967
- Donepezil, for dementia-related behavioral symptoms, in nursing home residents, 990
in Alzheimer's disease, vascular dementia, and mixed dementia, 950-952, 966
in Parkinson's disease with cognitive impairment, 961, 969
in schizophrenia in older adults, in antipsychotic augmentation, 926, 933-934
- Dopamine, extracellular levels of, with cocaine and amphetamine use, 540
- Dopamine agonists, in bipolar depression, 357-358
- Dopaminergic neurons in addiction, 742
- Dopamine transporter (DAT), in regulation of extracellular dopamine, 742-743
- Drinking limits, definition of, 897-898
- Drug abuse, prevalence of, in bipolar disorder, 416
- Duloxetine, in elderly patients, 828
- Dyslipidemia, obesity and, 11
with atypical antipsychotics, 49
- Dysphasia, 518-521
- Dyspraxia(s), 533. See also *Praxis*.
affect, 538, 540
agnosia, 529, 533-536
assessment of, 529
disconnection syndromes, 532, 534
executive function, 530-531, 537-538
interhemispheric integration, 532, 534
neuroanatomy of, 530
perceptual disturbances, 536, 538, 540
speech, 539, 541
thought processes, 534, 536, 539
to auditory verbal command, 531
to object cue command, 532
to pantomime demonstration command, 532
- Dysthymia, late-life, cognitive behavioral therapy for, 811-812
interpersonal psychotherapy for, 813
obesity and, 108
- Dystonia, acute neuroleptic-induced, causes of, 256
characterization of, 256
pharmacologic treatment of, 259
-
- E**
- Echoic memory, 524
- eDiets.com, components of, 174, 185-186
cost of, 177, 185-186
outcomes of, 186
- EEG (electroencephalogram), in diagnosis of frontal lobe seizures, 644-645
in nonconvulsive status epilepticus, 656-657, 661
- Electroconvulsive therapy (ECT), in bipolar depression, 357
in bipolar disorder, 366
in geriatric depression, 829-830
- Emotion, functional neuroanatomy of, 540
- Emotional processing, in bipolar disorder, functional magnetic resonance imaging and, 455
- Encoding, in memory, 582-583
- Energy balance, CNS regulation of, 25-38

- environmental factors and, 16
 genetic factors and, 16
 in weight control, 134
 regulation of, arcuate nucleus of
 hypothalamus in, 28-30
 ghrelin in, 27-28
 insulin in, 27
 leptin in, 26-27
 neurochemical systems in, 26-33
 regulation of body weight and, 12,
 15-16
- Energy density, satiety and, 123-124
- Environment, and weight gain, 16
 modification for weight control, 16-18
- Environmental change, in obesity
 prevention, legislative approaches to,
 245-246
 policy approaches to, 241,
 248-250
- Environmental stress, interaction with
 genetic factor, in affective illness, 490
- Epilepsia partialis continua, 640, 649
- Epilepsy. See also *Frontal lobe seizure(s)*.
 PET in localization of focus in, 563
- Executive control, actor-centered nature of,
 573-576
 internal representations and, 568
 mental flexibility and, 568
 nature of, 567-569
 neuroanatomic structures in, 569
 neuropsychological measures of,
 569-570
 prefrontal lobes in, integrative role of,
 573-574
 test batteries for, 570-572
- Executive Control Battery (ECB), in
 evaluation of executive dyscontrol
 syndrome, 571-572
 subtests of, 572
- Executive dyscontrol syndrome, Executive
 Control Battery for, 571-572
- Executive dysfunction, in cerebral white
 matter dementia, 694
- Executive function, 530. See also *Working
 memory*.
 assessment of, 537
 clinical conditions requiring,
 577-578
 conceptual foundations of, 530-531
 in bipolar disorder, functional
 magnetic resonance imaging and,
 456
 inhibitory control domain in, 531
 in schizophrenia, 620-621
 deficits in, as predictive of
 self-care deficits, 620
 functional relevance of,
 620-621
 operations in, 537
 working memory, 568
- Executive function syndromes, 538
- ## F
- Factitious disorders, neuropsychiatric
 assessment of, 545-546
- Family focused therapy (FFT), in bipolar
 disorder, 366, 374, 376-377, 379
- FDG-PET (fluorodeoxyglucose)-PET, 561,
 646
- Finnish Diabetes Prevention study,
 behavioral treatment in, 151
 low-fat diets and, 125, 126
- Fluorodeoxyglucose-positron emission
 tomography (FDG-PET), 561, 646
- Fluoxetine, in Alzheimer's disease, 955, 967
 in elderly patients, 828
 mania and, 360
 neurogenic effect of, in healthy, naive
 rodents, 405
- Fluphenazine, in schizophrenia in older
 adults, 917
- Fluvoxamine, in Alzheimer's disease, 955,
 967
- fMRI (functional magnetic resonance
 imaging), emotional processing and
 executive function in, 455-456
 in bipolar disorder, 454-455
 emotional processing tasks and,
 455
 executive function tests and, 456
 of white matter, 689
- Food, in schools, prevention of obesity in
 children and, 242-243
- Food environment, in obesity prevention,
 food industry and policy discussions
 and, 247
 policy approaches to, advertising
 in, 249
 priorities and suggestions,
 248-249
 policy changes and, 243-244
- Food intake, drug reduction of, 195-206
 in obesity prevention, 244-245
- Freud, S., 507

- Frontal lobe dementia, memory dysfunction in, 592
- Frontal lobe dysfunction, executive functions in. *See Executive control, neuropsychologic assessment of, 567-580*
- without structural damage, 577
- Frontal lobes, anatomy of, 635-637
- in working memory, 576
- Frontal lobe seizure(s), **635-562**. *See also Epilepsy.*
- absence and spike-wave stupor, 641-642, 648
- anatomy of frontal lobes and, 635-637
- benign, with frontocentral spike, 643
- bizarre hyperactive, 638-640
- causes and pathophysiology of, 642-644
- clinical characteristics of, 636-638
- diagnostic evaluation of, EEG in, 644-646
- differential diagnosis and distinction from psychiatric disorders, 646-648
- focal clonic and epilepsy partialis continua, 640
- in Rasmussen's encephalitis, 644
- nocturnal, autosomal dominant, 643
- nonconvulsive status epilepticus and, 637
- tonic, 640-641
- treatment of, pharmacologic, 648-649
- surgical, 649
- vagal nerve stimulator implantation, 649
- Frontal lobe syndrome, in schizophrenia, 577-578
- in traumatic brain injury, 577
- Functional adaptation skills training (FAST), in schizophrenia in older adults, 928-930
- G**
- Gabapentin, 314-315
- dosing of, 315
- for dementia-related behavioral symptoms, in nursing home residents, 991
- in acute mania, 315
- in bipolar depression, 356
- in bipolar disorder, in children and adolescents, 391
- maintenance efficacy of, 315
- tolerability of, 316
- Galantamine, in vascular dementia, and mixed dementia, 951, 966
- Generalized anxiety disorder, antidepressants for, 890
- benzodiazepines for, 889-890
- in late life, cognitive behavioral interventions for, 873-879, 884-886
- trial limitations in, 891-893
- pharmacological interventions for, 890-891
- Generalized convulsive status epilepticus (GCSE), incidence of, 655
- nonconvulsive status epilepticus and, 655
- Genetics, association studies in, 482
- basic concepts and definitions in, 481-482
- in bipolar disorder, **481-498**
- clinical subtyping approach to, 488-491
- familial aggregation in, of bipolar II disorder, 489
- of comorbid panic and anxiety symptoms, 489
- of lithium responsiveness, 489-490
- of psychosis, 489
- future diagnostic tests and treatments and, 491-492
- research in pathogenesis of, 491-492
- linkage studies in, 481-482
- Genetic syndromes, frontal lobe seizures and, 642-643
- Geriatric anxiety disorders, cognitive behavioral interventions for, 873-879
- psychopharmacological interventions for, 880-883
- Geriatric depression, brief preventive interventions in, 792-797, 799
- combination with risk factor abatement, 799
- effectiveness of, 794, 798
- evidence-based review of, 793-795
- feasibility of, 794, 796-797
- research proposals for, 799-800
- types of, 799
- brief psychodynamic therapy for, 813-814
- clinical epidemiology of, 1080-1081
- comorbidity in, cognitive impairment and structural abnormalities, 822

- medical, 822-824
 - psychiatric, 822
 - electroconvulsive therapy for, 829-830
 - evidence-based psychotherapeutic interventions for, **805-820**
 - interpersonal psychotherapy for, 812-813
 - medication-psychotherapy combination for, 815-816
 - pharmacologic interventions for, **821-835**
 - augmentation strategies in, 830-831
 - evidence-based literature review and analysis in, 824-826
 - in maintenance treatment and relapse prevention, 827, 829
 - in psychotic depression, 829
 - results and meta-analyses, 826-828
 - serotonin-norepinephrine reuptake inhibitors, 826, 828-829, 831
 - SSRIs, 826-831
 - tricyclic antidepressants, 826-827, 830
 - psychotherapies for, 810-816
 - behavioral and cognitive-behavioral, 810
 - future research in, 816-817
 - in dysthymia, 811-812
 - in major depression, 810-813
 - literature reviews of, 806-807
 - treatment outcome research, 808-809
 - reminiscence therapy for, 814-815
 - risk factor abatement program for, 795, 799
 - risks/factors and brief interventions for, **785-803**
 - risk factors for, evidence-based review, 786-791
 - meta-analyses results, 788, 791
 - research proposals for, 799-800
 - summary of prospective studies of, 786-790
 - validity of studies, 787-788, 792
 - suicidal ideation or suicidality in, 831
 - white matter abnormalities in, 696-697
- Geriatric psychiatry
- evidence-based, **763-784**
 - adequacy of scientific evidence in, 774-775
 - application of research to practice and, efficacy *versus* effectiveness in, 765-767
 - constitution of evidence in, 767-768
 - evidence-based medicine and, defined, 768-769
 - evidence-based practices in, 771-773
 - importance for improving outcomes for older persons, 764-765
 - incorporation of patients' preferences in, 770-771
 - individualization of evidence in, 770, 776-777
 - limitations and caveats in application of, 774
 - limitations in, of data from conventional and randomized clinical trials, 775-776
 - of pooled data and meta-analyses, 778-779
 - mental health evidence-based practitioners in, selection and definition of, 777-778
 - practice as evidence-based clinician, 773-774
 - report of evidence by researchers, bias in, 779
 - use of best scientific evidence in, 769-770
- Gerstmann syndrome, 539-540
- Glial cells, reduction of number, size, and density of, in bipolar disorder, 408
- Global functioning, improvement in, in home- and community-based care, 1053
- Glucagon, pancreatic, food intake reduction and, 205
- Glucagon-like peptide-I, food intake reduction and, 205
- Glucocorticoid receptor (GR), abnormalities of, hypercortisolemia and, 474-475
 - in depression, 471
 - treatment effect on, 474
- Glucocorticoid receptor (GR) agonists, type II, in HPS dysfunction, 476
- Glucocorticoid receptor (GR) antagonists, in mood disorders, 476-477
- Glucocorticoids, functions of, 469-470
 - in energy balance regulation, 32-33
 - effects on CNS melanocortin systems, 33
- Glycemic index, definition of, 120
- satiety and, 122-123

Glycerophosphocholine (GPC), on proton magnetic resonance spectroscopy, in bipolar disorder, 451

Graphical Sequence Test, in Executive Control Battery, 572

Gray matter, in bipolar disorder, alterations in, 406-407
regional-specific, 407-408
volumetric study of, 406-407

Group psychoeducation, in bipolar disorder, 375-376, 379

Group therapy, in chronic pain patient, 726-727

H

Haldol, in schizophrenia in older adults, 918-919, 921-922

Haloperidol, for dementia-related behavioral symptoms, in nursing home residents, 988-990
in Alzheimer's disease, vascular dementia, mixed dementia, 945-946, 948, 964
in rapid tranquilization of violent patient, 709

Health care professionals, attitudes toward obese persons, 40

Health Management Resources weight loss program, components of, 174, 180-181
costs of, 176, 180-181, 185
outcomes of, 181
studies of, 189

Health-related quality of life, improvement in, in home- and community-based care, 1052

Health-related quality of life (HRQL), obesity and, 43-44

High-protein diets, 128
efficacy of, 128-129
versus low-protein diets, 129

Hippocampus, in memory, 587-589, 608-609
on structural magnetic resonance imaging, in bipolar disorder, 446

Home-based mental health services, evidence-based study of, discussion of, 1043, 1056-1058
effectiveness of, 1043
method in, 1041-1042
methodological considerations, 1057

multidisciplinary outreach program for older adults, 1046-1047
results in, 1042-1043
in late-life mental illness, evaluation studies of, 1044-1047
outcomes of quasi-experimental and uncontrolled cohort studies, 1052-1055
outcomes of randomized controlled trials, 1048-1051
research challenges in, 1057

Huntington's disease, 276-281
and related disorders, 275-290
as trinucleotide repeat disease, 275-276
clinical features of, 276-277
cognitive symptoms in, 278-279
genetics and disease mechanism in, 277
counseling and, 278
transmission as autosomal dominant trait, 276-277
neurological symptoms in, progression of, 277
neuropathology of, 278
psychiatric symptoms in, 279-280
psychotic symptoms in, 180
treatment of, research investigation for, 280-281

Hypercortisolemia, cognitive defects in, 475

Hypomania, with continuation of antidepressants, 362

Hypothalamic-pituitary-adrenal (HPA) axis, abnormalities in, in children of bipolar parents, 473-474
cortisol in, 470-471
dysfunction of, as trait marker in bipolar disorder, 473
therapeutic targets for, 476-477
function of, 470-471
glucocorticoids and, 469-470
hyperactivity of, characterization of, 471-472
in bipolar disorder, 469-480

Hypothalamus, arcuate nucleus of, in energy homeostasis, 28-30

I

Ictal SPECT (ICT-SPECT), 646

IDEX SPECT (¹²⁵I-iododexetimide) SPECT, 563

- Improving mood: providing access to collaborative treatment (IMPACT), case study of evidence-based medicine use, 1079-1092
 clinical epidemiology of late-life depression and, 1080-1081
 comparison with care as usual, 1082-1083
 components of, 1081
 depression care manager in, 1081
 depression management in primary care and, 1063-1066, 1070
 description of, 1081
 development of intervention strategy based on existing evidence base, 1080-1081
 evaluation of effectiveness and cost-effectiveness in diverse health care settings, 1082-1083
 from research to practice, adaptations for implementation, 1087
 challenges in, 1088-1089
 consultation with experts in, 1085-1086
 dissemination of, external opportunities and, 1087-1088
 framework for, 1084-1085
 importance of key stakeholders to, 1087r
 increase in supply and demand for, 1085
 maintenance of at trial sites, 1083-1084
 organizations with sustained program, 1086
 researchers vs. academics and, 1086-1087
 training key clinical staff and, 1085
 web site information for, 1084
 problem-solving treatment for primary care training in, 1081
- Impulsivity, 703
- Integrated Group Therapy, in bipolar disorder and substance use disorder, 422
- Intrahemispheric integration, 532, 534
- Intermittent exercise, 147
- Internet, commercial weight loss programs on, 174, 177, 185-186
- Interpersonal psychotherapy, for late-life depression, 812-813
- Interpersonal social rhythms therapy (IPSRT), in bipolar disorder, 373, 374, 377, 379
- Interpersonal therapy, in bipolar disorder, 366
- Iowa Gambling Test, of decision-making impairment in damage to ventro-medial prefrontal cortex, 575
- Irritability, in Huntington's disease, 279
-
- J**
- Jenny Craig, components of, 174-176, 178
 costs of, 176, 178
 outcomes of, 178
-
- K**
- Ketamine infusions, in neuropathic pain, 729-730
- Kindling model, in epilepsy and bipolar disorder, 301-302
-
- L**
- Lamotrigine, 309-310
 dosing of, 311-312
 in acute mania, 310
 in bipolar depression, 310, 354-356, 363-364, 365
 in bipolar disorder, cognitive function and, 435
 in children and adolescents, 390-391
 in elderly/older patients, in continuation-maintenance therapy, 856-857, 859
 maintenance efficacy of, 310-311
 tolerability of, 312-313
- Language, assessment of, 517, 522
 conceptual foundations of, 516, 522
 dysphasias in, 518-521
- Language skills, in schizophrenia, 619-620
- LA Weight Loss, components of, 174, 178
 costs of, 176, 178
 outcomes of, 179
- Leptin, decrease in food intake and, 204
- Lifestyle history, 92-93
- Lifestyle modification, for weight control, 172
- Linkage regions, in bipolar disorder, problems in identification of, 484-485
 locus heterogeneity, 484
 phenotype definition, 484-485
 sample size, 485

- Linkage studies, 481-482
 in bipolar disorder, 482-484, 490
 meta-analyses of, 483-484
- Lithium, in bipolar depression, 353-354, 363
 in bipolar disorder, in children and adolescents, 388-390
 in elderly/older patients, 839-845, 850
 with comorbid alcohol and marijuana dependence, 420-421
 in elderly/older patients, considerations with, 860-861
 efficacy of, 850
 in continuation-maintenance therapy, 858-859
 side effects of, 839-845
 in vitro studies of, of neurogenesis and proliferation of progenitor cells, 402
 relevance to treatment of bipolar disorder and, 403
 movement disorders with, 255
 neurogenic effect of, in healthy, naive rodents, 405
 neuroprotective effects of, on magnetic resonance spectroscopy studies, in bipolar disorder, 453
 responsiveness to, familial aggregation in, 489-490
 weight gain with, 51-52
 with antidepressant, 353-354
- Locomotor sensitization, from nicotine and psychostimulant exposure, 741
- Long-term memory (LTM), 582
 neuroanatomic model of processing in, 590-591
 neuronal processes underlying, 587
- Low-carbohydrate diets, comparison with low-fat diet, 130
 efficacy of, 130-131
 summary of findings with, 131
- Low-fat diets, Diabetes Prevention Program trials of, 125-126
 Dietary Approaches to Stop Hypertension, 124-125
 efficacy for weight loss, 124-126
 examples of, 124
 Finnish Diabetes Prevention study, 125, 126
 long-term effect of, 128
 PREMIER trial, 124-125
- Low-glycemic index diets, 132
 effects on hunger and weight loss, 132-134

- studies of, in adolescents, 133-134
 in children, 132-134
 in hyperinsulinemic women, 133
 in nondiabetic men, 133-134

M

- Macronutrient(s), body weight regulation and, carbohydrates, 119-120
 glycemic index and, 120, 122-123
 simple and complex, 119
 dietary fat, 118-119
 protein, 119
 energy density of, 120-121
 satiety and, 121-122
- Magnetic resonance imaging (MRI), functional, in bipolar disorder, 454-456
- Magnetic resonance spectroscopy (MRS), future of, 559-560
 in bipolar disorder, neuroprotective effects of lithium in, 453-454
 phosphorus, 452-453
 proton, 450-452
 in parkinsonism, 559
 in vivo measurement of psychoactive drugs in brain, 559
 metabolic and biochemical information in, 558
 nuclear, in bipolar disorder, 451-453
 nuclei studied with, 558
 of white matter, 688
 point-resolved, 558
 results in autistic children study, 559
 stimulated echo acquisition method in, 558-559
 vs. nuclear MR, 557-558
- Major depression, geriatric, cognitive behavioral therapy for, 810
 comparison with other therapies, 810-811
 interpersonal psychotherapy for, 812-813
 in elderly patient, incidence of, 785
 interpersonal psychotherapy for, 812-813
 medication and psychotherapy combination for, 815-816
- Major depressive disorder (MDD), substance abuse in, 416
- Malinger, neuropsychiatric assessment of, 545-546
- Mania, animal models of, 403-404
 antidepressant-induced, 358-361
 carbamazepine in, 306-307

- gabapentin in, 315
 - lamotrigine in, 310
 - oxcarbazepine in, 308
 - substance use disorders and, 416
 - topiramate in, 313
 - valproate/divalproex sodium in, 302, 304
- Manic states, in elderly/older patients, lithium for, 850
- Manual Postures Test, in Executive Control Battery, 572
- Massage therapy, in neuropathic pain, 731
- McLeod syndrome, 284
- Meal replacements, with behavioral treatment, in obesity, 158-159
- Medial diencephalon, in memory, 588-589
- Medial temporal lobe amnesic syndrome, **599-611**
 - following bilateral temporal lobe removal, case history, patient HM, 601-603
 - maze-learning task and, 603-604
 - mirror drawing task, 604-605
 - spatial relationships learning and, 604
 - visuo-motor skill acquisition and, 604
 - critical lesion for, 606-607
 - episodic vs. semantic memory and, 605-606
 - following unilateral temporal lobe removal, case examples, 599-601
- Medial temporal lobes, in memory, 587-588
- Medical model, of obesity, 240-241
- Medifast weight management program, components of, 174, 183-184
 - costs of, 176, 184
 - outcomes of, 184
- Melanin-concentrating hormone, food intake reduction and, 205
- Memantine, in Alzheimer's disease, 951-952
- Memory. See also *Amnesia*.
 - as change of synaptic structure and efficacy, 585-586
 - assessment of, 523-525
 - conceptual divisions of, 581-584
 - antegrade and retrograde, 583
 - declarative *versus* nondeclarative, 584
 - encoding, retention, and retrieval processes in, 582-583
 - episodic, 584
 - recent and remote, 584
 - semantic, 584
 - short- and long-term memory, 582
- declarative, medial temporal region in, 606-607
- deficits in, in Huntington's disease, 278-279
- disorders of, 523-525, **581-597**
 - in clinical populations, 591-594
- neuroanatomic correlates of, 587-590
- neurobiologic bases of, 585-587
- potentiation of, long-term, 587
- posttetanix, 586
- processes in, 523
- remote, hippocampus in, 608-609
- retrieval deficits in, in cerebral white matter dementia, 694
- systems in, 524
- Mental health, obesity and, 25
- Mental health care, access to, for homebound and frail community-dwelling older adults, 1040-1041
- Metabolic syndrome (syndrome X).
 - bariatric surgery effect on, 229-232
 - comorbid conditions in, diabetes mellitus, type 2, 229
 - gastroesophageal reflux, 229-230
 - hormone imbalance and cancer, 230-231
 - hypertension, 230
 - idiopathic intracranial hypertension, 230
 - musculoskeletal problems, 231-232
 - reduction of surgical diseases, 232
 - respiratory disease, 229
 - urinary urgency and incontinence, 231
- diagnostic criteria for, 99
- obesity and, 11
- orlistat for, 209-210
- psychosocial effects of, 231
- Metabolism, drug alteration of, 206-210
- Metrifonate, in Alzheimer's disease, vascular dementia, and mixed dementia, 950

- Mianserin, in schizophrenia in older adults, in antipsychotic augmentation, 926-927, 933
- Mifepristone (RU-486), in bipolar depression, 358
in bipolar disorder, 477
cognitive function and, 435
in depression, 476-477
in restoration of hypothalamic-pituitary-adrenal axis function, 477
- Modafinil, in cocaine addiction, 740
- Moderate-fat diets, 125, 127
efficacy of, 128
- Monoamine oxidase A, in bipolar disorder, association studies, 487-488
- Monoamine oxidase inhibitors, mania and, 361
rapid cycling and, 359
- Mood cycling, in children and adolescents, medication-induced, 387
with monoamine oxidase inhibitors, 359
- Mood disorders, in spinocerebellar ataxias, 282
- Mood stabilizers, for agitation in dementia, 971
in Alzheimer's disease, vascular dementia, and mixed dementia, 953-954, 967
in bipolar depression, 363, 365
in children and adolescents, 394
in bipolar disorder, cognitive function and, 434-435
in children and adolescents, 388-391
neuroprotective aspects of, **399-414**
neuroprotective characteristics of, 399-400
biochemical support of, 400
in cultured cells, 401-403
limitations of, 401
variations in, 401-402
neuroprotective/neurogenic properties of, future studies of, 405-405
in animal models, 403-404
in animals, 403-406
in healthy, naive rodents, 404-405
in humans, 406-408
weight gain with, 51-52
- Morbid obesity, surgical intervention for, 170-171. See also *Bariatric surgery*.
- Motor performance tasks, in bipolar disorder, functional magnetic resonance imaging and, 456
- Motor Sequences Test, in Executive Control Battery, 572
- Movement disorder(s). See also *specific*.
antipsychotic-induced, 47
behavioral symptoms in, 275
Huntington's disease and related disorders, **275-290**
neuroacanthocytosis, 283-285
neuroleptic-induced, **255-274**
spinocerebellar ataxias, 281-282
Wilson's disease, 282-283
- MRI (magnetic resonance imaging), appearance of image in, 552-555
balance or proton density sequences in, 552
contraindications to, 553-554
diffusion tensor imaging, of brain tissue microstructure and white matter tracts, 555-556
enhanced, 554
fluid attenuation inversion recovery sequences in, 552, 554
functional. See *fMRI (Functional magnetic resonance imaging)*.
in bipolar disorder, **443-467**
in diagnosis of frontal lobe seizures, 645
interaction between external magnetic fields and patient tissue, 551
of white matter, 688
functional, 688-689
with diffusion tensor imaging, 688
with magnetization transfer imaging, 688
structural, anatomic findings on, in bipolar disorder, 444-450
unenanced, axial, 552-553
fluid attenuation inversion recovery, 554
volumetric, in quantitative assessment of regional atrophy, 555
in study of patients with schizophrenia, 555
- Myoinositol, on proton magnetic resonance spectroscopy, in bipolar disorder, 451-452
- N**
- N-acetylaspartate, on proton magnetic resonance spectroscopy, in bipolar disorder, 450-451

- Naltrexone, in alcohol dependence, 903-904, 906
- Narcotic analgesic, intrathecal, in neuropathic pain, 730
- Nerve blocks, in neuropathic pain, 730
- Neuroacanthocytosis, classes of, abetalipoproteinemia, 284-285 chorea-acanthocytosis, 284 McLeod syndrome, 284 clinical symptoms of, 284 manifestations of, 283-284
- Neurobehavioral syndromes, focal, in cerebral white matter disorders, 694-695
- Neurodegenerative diseases, bipolar disorder *versus*, 408 pharmacologic interventions for, antipsychotics, 943-949, 958-959, 963-965 cognitive enhancing agents, 950-952, 961-962, 965-966, 969 mood stabilizers, 953-954, 967 psychosis and agitation in, pharmacologic interventions for, 941-983, evidence-based studies of, 942-943 rating instruments used in studies, 963
- Neuroimaging, and neurocognitive abnormalities, in bipolar disorder, 438 functional, 556-560 MR spectroscopy, 557-560 functional MRI, 556-557 advantages of *vs.* SPECT and PET, 556 in preoperative brain mapping, 557 in neuropsychiatry, 549-566 modalities for, 549-550 of white matter, structural, 688 positron emission tomography, 560-563 structural, CT, 550-551 MRI, 550-556
- Neuroleptic-induced movement disorder(s). See also *Tardive dyskinesia*. acute, 256-262 akathisia in, 257-259 dystonia in, 256-257 neuroleptic malignant syndrome, 260-262 parkinsonism in, 259-260 tardive dyskinesia, 262-269 behavioral syndromes in, 263 movements in, 262-264 onset of, 263-264 orobuccal-lingual-facial musculature in, 262-263
- Neuroleptic malignant syndrome, diagnosis of, 261 differential diagnosis of, 261 progression in, 261-262 symptoms of, 260 treatment of, 262
- Neuronal nicotinic acetylcholine receptors (nAChRs), in stimulation of neurotransmitters in addiction, 742
- Neuropathic pain. See also *Pain*. adjunctive medications for, 729-730 complementary strategies in, 731 diagnosis of, activities of daily living and, 723-724 ancillary studies in, 725-726 inciting event in, 723 medical comorbidities, 724 physical examination in, 725 presenting characteristics of pain in, 723 prior psychiatric conditions, 724 treatment expectations, 724 interventional strategies for, 730-731 pharmacologic therapy for, 727-729 physical therapy for, 731 psychotherapies for, 726-727
- Neuropathic pain syndrome(s), complex regional pain syndrome, 721-722 diabetic peripheral neuropathy, 720-721 low back pain, 719-720 pain secondary to central nervous system injury, 722-723 postherpetic neuralgia, 720
- Neuropeptide-Y (NPY), in energy balance regulation, 28-30
- Neuropeptide-Y (NPY) antagonism, weight reduction with, 205
- Neuropsychiatric assessment, 507-547 amnesic syndromes in, 526, 527 aphasias in, 528-521 arousal in, 517-518 attentional components in, 514 attentional syndromes in, 515 attention in, 515, 519-521 tests of, 514, 515 awareness in, 513, 518, body representation in, 525, 529 clinical history in, 510-511, 516 clinical inventory in, 508, 512

Neuropsychiatric assessment (*continued*)

- cognitive/affective/behavioral assessment constructs in, 517-527
- conceptual foundations of, 508, 512
- consciousness in, 517
- contemporary approach to, 509-515
- diagnostic humility in, 515-516
- diagnostic tests inventory in, 543-545
- domain overlap in, 513-514
- dysphasias in, 518-521
- hemispheric dominance in, 518-519
- hierarchy of brain functions in, 513
- historical foundations of, 507
- instruments in, standardized, 509
- language in, 516, 522
- levels of, 514-515
- malinger in, 545-546
- memory in, 522-525
- neurologic examination in, 541-542
- neurologic testing in, 515
- neuropsychiatric clinical history in, informants, 517
- patient, 510-511, 516
- organizational principles in, 512-513
- phenomenological scope of, 509, 512
- praxis in, 527-541
- psychodynamic context of, 541
- somatoform and factitious disorders in, 545-546
- visuospatial processing function in, 525, 527-528

Neuropsychiatric syndromes, mixed type, 539-541

Neuropsychiatry, neuroimaging in, 549-566

Neuropsychologic assessment, of frontal lobe dysfunction, 567-580

Neuropsychologic evaluation, 429-430

- cognitive domains in, 429-430
- neuropsychological functions by lobe in, 431
- tests in, 428-429
- factors affecting, 429

Neuropsychology, definition of, 428

Neurotensin, defined, 738

- description of, 743-744
- in mediation of antipsychotic drug effect, 744
- in regulation of dopaminergic pathways, 744

Neurotensin analogues, NT69L in blocking nicotine-induced sensitization, 745

- with affinity for human neurotensin receptors, 745

Neurotensin receptor antagonists, nonpeptide, in cocaine and amphetamine sensitization, 744-745

- SR142948A and SR48692, 744-745

Neurotensin receptor antagonists, nonpeptide, 744

Nicotine, blockade of, and smoking increase, 739

Nicotine addiction, in schizophrenia, 737-738

- neurobiologic basis of, 737-751

Night eating syndrome, 60-64

- criteria for, provisional, 60
- eating *versus* sleep disorder and, 62
- familial link in, 62
- features of, 61-62
- obesity and, 110-111
- prevalence of, 60-64-61
- psychiatric comorbidity with, 61-62
- treatment of, 63

Nonalcoholic fatty liver disease, obesity and, 14

Nonconvulsive status epilepticus (NCSE), 653-664. See also *Status epilepticus*.

- absence status, 654
- case presentations and analysis, 657-660
- clinical characteristics of, 655-656
- complex partial status, 654
- definitions of, 654
- diagnostic approach to, 656-657
- frontal lobe seizures and, 637
- pharmacologic treatment of, 661
- prognosis in, 660-661
- vs.* convulsive status epilepticus, 653

Nurse-based outreach and case management, in home- and community-based treatment, of older adults, 1044-1045

O

Obese patient, assessment of readiness to change behavior in, 100-101

- behavioral assessment of, 105-112
- binge eating and, 108-110
- comorbid psychopathology in, 107-109
- data gathering in, 106-107
- diet composition in, 110
- food in, availability of, 109
- intake amount and pattern and, 109-110

- history of prior treatments and weight loss attempts in, 106-107
 - night eating syndrome in, 110-111
 - physical activity level in, 111
 - psychosocial factors in, 107-111
 - self-report inventories in, 107
 - biological factors and, 111-112
 - examination of, BMI in, 94-97
 - cardiorespiratory fitness in, 95-96
 - organ systems review in, 98-99
 - waist circumference in, 95
 - high-risk, identification of, 97, 99
 - identification and evaluation of, 90
 - lifestyle history in, diet and physical activity, 92-93
 - medical evaluation of, obesity-focused history in, chronology of weight gain in, 91
 - excess weight effect on health, 92
 - expectations from weight management program, 92
 - response to weight loss attempts, 91-92
 - screening tests in, 99-100
 - psychiatric/psychological history in, 93-94
 - medication history in, 94
 - referral to weight loss programs, 172
 - social history in, 93
- Obesity.** See also *Overweight: Weight gain*.
- as epidemic, energy balance and, 12, 15-16
 - environmental changes and, 16-18
 - interaction of biology, behavior, environment in, 18-19
 - prevention and, 20
 - strategies to address, 19-20
 - behavioral assessment and treatment of, **105-116**
 - behavioral treatment of, **151-170**
 - biases toward, 40
 - binge eating disorder and, 55-60
 - BMI and, 1-2
 - body image and, in adulthood, **69-87**
 - causes of, 235-240
 - comorbidities and complications of, 13, 107-109, 229-232
 - psychopathologic, 40-46
 - dietary approaches to, **117-139**
 - drug treatment of, **193-217**
 - alteration of metabolism with, 206-210
 - attitude toward patient relapse and, 194
 - β -adrenergic receptor agonists in development, 212
 - caffeine in, 210-212
 - drugs in clinical trials, 202-204
 - ephedrine in, 210-212
 - negative aspects of, 193-194
 - patient selection for, 193
 - peptides in early stages of development, 204-206
 - reduction of food intake with, 195-206
 - sympathomimetics in, approved, 195-201
 - nonapproved, 201-202
 - valvular heart disease with, 194
 - weight loss plateau and, 194-195
- eating disorders and, **55-67**
- epidemic of, **1-23**
- health risks of, 8-15
- in children and adolescents, 14-15
- increasing in Americans, 7-8, 11-12
- medical evaluation of, **89-103**
- night eating syndrome and, 60-63
- organ systems affected by, 89
- physical activity recommendations in, **141-150**
- prevalence of, 1-7
- age groups and, 7-9
 - in adults, 2-3
 - in children, 7, 9-10
 - in low SES and minority individuals, 4-6
 - over time, 2-6
 - proportional increase in population, 7
 - racial and ethnic, 2-3
- prevention of, 20
- environmental changes for, 241
 - in children, food in schools and, 242-243
 - physical activity in schools and, 245-248
 - recommended actions for, 242-244
- psychiatric status and psychiatric medications, **39-54**
- psychological correlates of, 39-40
- public health and, 20-21
- public policy and, **235-252**
- risks for, birth weight, 112
- fat cell size and numbers, 112
 - genetic, 111-112
- treatment of, guide to, 112-113
- outcomes of, possible, 19
 - surgical, **219-234**

Obesity (continued)

- waist circumference in, 95
- comorbidities and, 112-113
- weight control programs for, 171-192

Obsessive-compulsive disorder, cognitive behavioral interventions for, in elderly patient, 886-887**Olanzapine, in acute mania, 340**

- in Alzheimer's disease, vascular dementia, and mixed dementia, safety and tolerability of, 972
- in Alzheimer's disease, vascular dementia, mixed dementia, 948-949, 964-965
- in bipolar depression, 336-337, 356
- in bipolar disorder, for continuation and maintenance therapy, 342-343
- in dementia, treatment recommendations, 976-977
- in dementia with Lewy bodies, 959
- in Parkinson's disease with psychosis, 958-959, 969
- in schizophrenia in older adults, 916, 919-924, 931, 933
- mortality risk with, 974
- with fluoxetine, in bipolar depression, 356

OPTIFAST weight management program,

- components of, 174, 182
- costs of, 176, 182, 185
- outcomes of, 182-183
- studies of, 189

Orlistat, in treatment of obesity, effects of, on glucose tolerance and diabetes, 208-210

- on lipids and lipoproteins, 207-208
- efficacy of, 206-207
- in combination with sibutramine, 210-211
- in obese patients with hypercholesterolemia, 208
- pharmacology of, 206
- safety of, 210
- summary of, 213

Overeaters Anonymous, components of,

- 174, 187-188
- costs of, 177, 188
- outcomes of, 188

Overweight. See also Obesity; Weight gain. BMI and, 1-2, 113**Oxcarbazepine, dosage and serum-level monitoring of, 309**

- in acute mania, 308
- in bipolar depression, 309
- in bipolar disorder, in children and adolescents, 390
- maintenance efficacy of, 309
- tolerability of, 309

P**Pain. See also Neuropathic pain.**

- acute, characterization of, 713
- processing of, 714
- chronic, characterization of, 713-714
- comorbidities in, 718-719
- defined, 714
- neuropathic, 717
- defined, 718
- neurotransmitters in modulation of, 716-717
- pathways in, ascending, 714-175
- descending, 715-716
- processing of, 714-717
- central nervous system in, 717-718

Panic disorder, cognitive behavioral interventions for, in elderly patient, 886

- pharmacological interventions for, 890

Para-amnesias, 527**Paralinguistic communication, 522-523****Parasomnias, vs. frontal lobe epileptic seizure, 648****Parkinsonism, neuroleptic-induced, causes of, 259**

- management of, 260
- symptoms of, 259

Parkinson's disease, antipsychotics for, efficacy of, 971

- pharmacological interventions in, safety and tolerability of, 975
- psychosis in, clozapine for, 978

Paroxetine, in elderly patients, 828**Paroxysmal nocturnal dystonia, vs. frontal lobe epileptic seizure, 648****Peptides, in reduction of food intake, 204-206****Perceptual disturbances, 536, 538, 540****Perphenazine, in Alzheimer's disease, vascular dementia, mixed dementia, 949**

- PET/CT fusion technique(s), coregistration of functional and anatomic data sets, 560-561
- PET/MRI technique(s), coregistration of PET and MRI images in, 561
- PET (positron emission tomography), applications of, 560
in central serotonin system study, 561-562
in neurodegenerative disorders, 561
molecular imaging agents in, 561
of white matter, 689
radionuclides in, 560
- Pharmacotherapy, in bipolar disorder, in children and adolescents, **385-397**
- Phendimetrazine, in obesity, 196
- Phentermine, in obesity, 196
- Phenylpropanolamine, blood pressure and, 200
- Phenytoin, 317
in bipolar disorder, acute efficacy of, 318
dosing of, 318-319
maintenance efficacy of, 318
tolerability of, 319
- Phonological fluency, in schizophrenia, 619
- Phosphorus magnetic resonance spectroscopy, in bipolar disorder, 452-453
- Phosphorylcholine (PPC), on proton magnetic resonance spectroscopy, in bipolar disorder, 451
- Physical activity
in obesity, **141-150**, 163-166
intermittent, 147
lifestyle approaches to, 147
modification of, pedometers in, 147-138
resistance exercise, 146-147
in obesity prevention, 242
in schools, 245-248
in weight loss, health benefits of, 165-166
long-term effects of, 164
in weight maintenance, mechanisms of action of, 164-165
preactivity screening for, 146-147
stage of motivational readiness for, 143-144
- Physical activity prescription, in overweight or obese adults, minimal dose of, 143-145
- Institute of Medicine
recommendations, 145
intensity of activity and, 145-146
monitoring of, 146
risk-benefit considerations, 145-146
- Physical environment, in obesity
prevention, policy approaches to, 249
- Physical therapy, in neuropathic pain, 731
- Pituitary gland, in structural magnetic resonance imaging, in bipolar disorder, 449-450
volume of, and hypothalamic-pituitary-adrenal axis dysfunction, 473
- Portion-controlled diets, with behavioral treatment, in obesity, 159
- Positron emission tomography. See *PET (positron emission tomography)*.
- Pramlintide, weight loss with, 206
- Praxis. See also *Dyspraxia(s)*, *neuroanatomy of*.
assessment of, 531
neuroanatomy of, functional, 530
- Prefrontal cortex, in memory, 590
in structural magnetic resonance imaging, in bipolar disorder, 444-446
- Prevention of suicide in primary care elderly: collaborative trial (PROSPECT), depression management in primary care and, 1063-1064, 1067, 1070-1071
- Primary care research in substance abuse and mental health for the elderly (PRISM-E) trial, depression management in primary care, 1062-1065
- Problem-solving therapy, in home- and community-based treatment, of older adults, 1044
- Progressive muscle relaxation therapy, in night eating syndrome, 63
- Proopiomelanocortin (POMC), in energy balance regulation, 28-30
regulation by peripheral signals, 28-30
- Propranolol, for dementia-related behavioral symptoms, in nursing home residents, 990, 992

- Psychiatric symptoms, improvement in, in home- and community-based care, 1055
- Psychogenic non-epileptic seizure, psychiatric comorbidity in, 647-648
vs. frontal lobe epileptic seizure, 646-647
- Psychogenic syndrome, diagnostic classification of, 545
- Psychogeriatric team treatment, in home-care of elderly, 1045
- Psychologic treatments, adjunctive to pharmacotherapy, 372
 rationale for, 372-373
 in bipolar disorder, brief cognitive and behavioral interventions, 374-375
 cognitive therapy, 374-375, 377-379
 controlled outcome trials of main models of, 378-380
 family focused therapy, 374, 376-377, 379
 group psychoeducation, 375-376, 379
 interpersonal social rhythms therapy, 374, 377, 379
 outcome trials, similarities and differences in, 378-380
- Psychosis, in bipolar disorder, familial aggregation in, 489
- Psychosocial treatment, in bipolar disorders, 371-384
- Psychostimulant abuse, neurobiologic basis of, 737-751
- Psychostimulant addiction, psychiatric disorders coexisting in, 740
- Psychotic disorders, in spinocerebellar ataxias, 282
- Psychotic patients, reasons for smoking, 738-739
- Public health model, of obesity, 240-241
- Public policy, in obesity, recommended actions, 242-244
 medical *versus* public health perspective on, 240-241
 obesity and, environmental contributors to, evidence for, 236-237
 food, 237-238
 physical activity, 239-240
 individual responsibility for, 235-236
 medical *versus* public health perspective on, 240-241
 prevention, 240-241
 public health model of obesity and, 240-241
- Pulse therapy, with corticosteroids or nonsteroid anti-inflammatory drugs, in neuropathic pain, 729
-
- ## Q
- Quality of life (QOL), bariatric surgery effect on, 231
 obesity and, 15
- Quetiapine, in Alzheimer's disease, 949, 965
 in bipolar depression, 337
 in bipolar disorder, for continuation and maintenance therapy, 341, 455
 with alcohol cocaine and alcohol dependence, 422
 with stimulant abuse, 421
 in Parkinson's disease with psychosis, 960, 969
 mortality risk with, 974
-
- ## R
- Rapid cycling, in bipolar disorder, 359
 in mania, 358-361
 monoamine oxidase inhibitor-associated, 359
 tricyclic antidepressant-associated, 359-360
- Rasmussen's encephalitis, 644
- Re-engineering systems for primary care treatment of depression (RESPECT-D), integrated management in primary care, 1063-1064, 1068-1069
- Reminiscence therapy, for late-life depression, 814-815
- Resistance exercise, 146-147
- Restraints, in emergent and imminent dangerous behavior, 708
- Retention, in memory, 582-583
- Retrieval, in memory, 583
- Reverberatory neuronal circuit, in memory, 586
- Review of systems, in neuropsychiatric assessment, 510
- Right frontal pathology, ego function deficit and, 677-678

- Right hemisphere, in delusional misidentification, 671, 675, 677
in ego disturbance and function, 677
- Rimonabant, in weight loss, 203
- Risperidone, cerebrovascular adverse events with, 973
for dementia-related behavioral symptoms, in nursing home residents, 988
in Alzheimer's disease, vascular dementia, mixed dementia, 947, 949, 964-965
in dementia, treatment recommendations, 976-977
in Parkinson's disease, safety and tolerability of, 975
in schizophrenia in older adults, 916, 919-921, 923-925, 931, 933
mortality risk with, 974
- Rivastigmine, in Alzheimer's disease, 952, 966
in dementia with Lewy bodies, 961, 969
in Parkinson's disease with dementia, 962, 969
in schizophrenia in older adults, in antipsychotic augmentation, 926, 934
- Rolandic epilepsy (benign epilepsy with frontocentral spike), 643-644
- S**
- Satiety, energy density of macronutrients and, 123-124
glycemic index and, 122-123
macronutrients and, 121-122
- Schizophrenia, attentional impairments in, 615-616
Capgras syndrome in, 666
cognition in, **613-633**
 substance abuse and, 622
 cognitive deficits in, and frank psychosis, 622-623
 cortical changes and, 623
 course of over lifespan, 622-623
 cognitive dysfunction in, antipsychotic mediations for, second-generation, 625-626
 behavior strategies for, 625-626
 functional outcome and, 624-625
 cognitive function in, assessment methods for, 623-624
 depressive symptoms in, in mediation of neurocognition and functional skills, 625

- executive deficit in, 578
executive functioning in, 620-621
functional MRI in, 557
in older adults, antidepressant augmentation in, 926-929, 933
antipsychotics in, 916-926, 931-935
evidence-based treatments for, **913-939**
 study limitations in, 934-935
 pharmacologic interventions in, 916-926, 931-935
 psychosocial interventions in, 926, 928-929, 928-931, 935
 language skills in, 619-620
 nicotine dependence in, 737-738
 obesity and, 46-47
 social cognition in, 621-622
 tardive dyskinesia in, 264-265, 270
 verbal learning and memory in, 618-619
 as predictors of social, adaptive, and occupational function, 619
 white matter abnormalities in, 696-697
 working memory in, 616-617
- Selective serotonin reuptake inhibitors (SSRIs), for dementia-related behavioral symptoms, in nursing home residents, 989, 991-992
in binge eating disorder, 57-58
in bipolar depression, 351-352
 in children and adolescents, 394
in dementia, efficacy of, 977
in elderly/older patients, side effects of, 848
in geriatric depression, 826-831
in neuropathic pain, 728
in night eating syndrome, 63
weight gain with, 50-51

Self-esteem, body image dissatisfaction and, 71-72

- Self-help programs, in weight control, 174
 Internet-based, 174, 177, 185-186
 organized, 174, 186-188
in weight loss, 186
 Overeaters Anonymous, 174, 177, 184, 187-188
 Take Off Pounds Sensibly, 174, 177, 187-188

Sensory therapy, for dementia-related behavioral symptoms, in nursing home residents, 987-989, 991, 999

- Serotonergic drugs, in weight loss, 201-202
- Serotonin (5-HT), in energy balance regulation, 30-32
- Serotonin-norepinephrine reuptake inhibitors (SNRIs), in geriatric depression, 826, 828-829, 831
- Serotonin selective reuptake inhibitors. See *Selective serotonin reuptake inhibitors (SSRIs)*.
- Serotonin transporter gene, 5-HTT, in bipolar disorder, association studies, 475
- Serotonin transporter (SERT), PET studies of, in epilepsy, 563
in mood disorders, 562-563
- Sertraline, for dementia-related behavioral symptoms, in nursing home residents, 989
in Alzheimer's disease, 957, 967
in elderly patients, 828
- Sexual abuse, obesity and, 108
- Short-term memory (STM), 524, 582
neural processes underlying, 586-587
- Sibutramine, in binge eating disorder, 58
in weight loss and maintenance, 197
in weight reduction, blood pressure management and, 200
clinical trials for weight loss with, 197
contraindications to, 200-201
dosage and dose effect of, 199
in hypertensive patients, 198-199
in patients with diabetes, 197-198
mechanism of action of, 212-213
- Single-photon emission CT. See *SPECT (single-photon emission CT)*.
- Skills training and health management, in schizophrenia in older adults, 929-931
- Sleep apnea, obesity and, 14
- Sleep deprivation, in chronic pain, 719
- Smoking cessation, in elderly patient, 904-905
in patients with schizophrenia, 738
- Social cognition, in schizophrenia, 621-622
- Sodium divalproex, in bipolar disorder, in children and adolescents, 390
side effects of, 390
- Sodium valproate, in Alzheimer's disease, vascular dementia, and mixed dementia, 954, 967
- Somatoform disorders, neuropsychiatric assessment of, 545-546
- SPECT (single-photon emission CT), in evaluation of seizure patient, 563
of white matter, 689
radioactive tracers in, 560
- Speech, 539, 541
- Spinal cord stimulation, in neuropathic pain, 730
- Spinocerebellar ataxia(s), autosomal dominant, 281
clinical manifestations of, 281-282
dementia in, 282
genetic etiology of, 281
psychotic disorders in, 282
- Status epilepticus. See also *Nonconvulsive status epilepticus (NCSE)*.
- Stimulants, in bipolar depression, 351
in children and adolescents, 394
movement disorders with, 255
- Stimulated echo acquisition method (STEAM), in MR spectroscopy, 558-559
- Stress, night eating syndrome and, 61
- Stress-vulnerability models, of mental disorders, 372
- Stroop tests, of executive control, 570
- Subcortical degenerative disease, memory deficits in, 592
- Subcortical nuclei, in memory, 590
- Substance abuse, in elderly patient, alcohol, 898-900
detoxification and withdrawal in, 904-905
evidence-based treatment of, 897-911
pharmacotherapy in, 903-904
prescription and over-the-counter medications, 900
prevention and early intervention approaches in, 901-902
screening and diagnosis of, 900-901

- treatment of, 902-903
- primary care research in substance
 - abuse and mental health for the elderly (PRISM-E) trial, 1062-1065
- Substance abuse/dependence, obesity and, 108
- Substance abuse disorders, comorbid with bipolar disorder, 373
 - in bipolar disorder, **415-425**
 - Integrated Group Therapy for, 422
- Substance use disorders, in bipolar disorder, carbamazepine in cocaine dependence, 420-421
 - causes of, 419-420
 - genetic vulnerability for, 420
 - impact of, 418-419
 - in adolescents, 388
 - lithium adherence and, 419
 - lithium vs. placebo in, 420-421
 - nonadherence and, 418
 - onset of mood symptoms and, 419
 - prevalence of, 415-417
 - risk factors for, 417-418
 - alcohol in mania, 417
 - cocaine in depression, 417
 - male gender, 417
 - mood state, 417
 - risk of violence in, 418
 - treatment in, 420-422
 - onset before mood symptoms, in bipolar disorders, 419-420
- Suicidal ideation, with atypical antidepressants, 1062
- Suicidal ideation/suicidality, in geriatric depression, pharmacologic treatment of, 831
- Suicide, risks for, Wilson's disease, 283
- Supplementary motor area (SMA) seizures, 640-641
- Sympathetic blockade, in neuropathic pain, 730
- Sympathomimetic drugs, in obesity, approved, efficacy of, 196
 - first generation, 196
 - pharmacology of, 195
 - safety of, 200-201
 - sibutramine, 196-200
 - nonapproved, bupropion, 201
 - serotonergic, 201-202
- in weight reduction, adverse effects of, 200

Syndrome X. See *Metabolic syndrome (syndrome X)*.

T

- Take Off Pounds Sensibly (TOPS), components of, 174, 187
 - costs of, 177, 187
 - outcomes of, 187-188
- Tardive dyskinesia. See also *Neuroleptic-induced movement disorder(s)*.
 - drug dose and duration of exposure in, 267
 - drug treatment of, 269
 - epidemiology of, 264-265
 - in schizophrenia, 264-265, 270
 - movements in, 262
 - orobuccal-lingual-facial musculature in, 262-263
 - natural history of, 265
 - onset of, 263
 - pathophysiology of, 268-269
 - changes in neurobiology and, 268, 270
 - dopamine supersensitivity hypothesis, 268
 - neurodegeneration hypothesis, 268-269
 - risk factors for, 265-267
 - spontaneous, 264
 - subsyndromes of, 263, 270
- Temporal lobe structures, in structural magnetic resonance imaging, in bipolar disorder, 446-447
- Thalamus, in structural magnetic resonance imaging, in bipolar disorder, 447-448
- Thioridazine, for dementia-related behavioral symptoms, in nursing home residents, 988-989
 - in schizophrenia in older adults, 917
 - weight gain with, 48
- Thiothixene, for dementia-related behavioral symptoms, in nursing home residents, 988
 - in Alzheimer's disease, vascular dementia, mixed dementia, 945, 964
- Thought processes, assessment of, 534, 539
 - disturbances of, 534, 536, 539
- Tiapride, in Alzheimer's disease, vascular dementia, mixed dementia, 947
- Tizanidine, in neuropathic pain, 729

- Tonic (supplementary motor area) seizures, 640-641
asymmetrical, 641
- Topiramate, dosing of, 314
in acute mania, 313
in binge eating disorder, 58
in bipolar depression, 313-314, 356
in bipolar disorder, in children and adolescents, 391
with alcohol dependence, 422
in weight loss, 202-203
maintenance efficacy of, 314
tolerability of, 314
weight gain with, 52
- Tower tests, of executive control, 569-570
- Training interventions, for dementia-related behavioral symptoms, in nursing home residents, 991-995, 999-1000
- Tramadol hydrochloride, in neuropathic pain, 729
- Transforaminal injections, in neuropathic pain, 730
- Trazodone, in Alzheimer's disease, 956, 968
in schizophrenia in older adults, in antipsychotic augmentation, 926-927, 933
- Tricyclic antidepressants (TCAs), in binge eating disorder, 58
in bipolar depression, 351-352
in children and adolescents, 394
in geriatric depression, 826-827, 830
in neuropathic pain, 728
rapid cycling with, 359-360
weight gain with, 50
- U**
-
- Unipolar depression, neuropsychologic deficits in, 432
- V**
-
- Valproate, for dementia-related behavioral symptoms, in nursing home residents, 991
in bipolar disorder, cognitive function and, 435
with alcohol abuse, 421
in elderly/older patients, considerations in, 860
efficacy of, 850-854
side effects of, 842-843, 845-848
in violent patient, 709
in vitro studies of, proliferation of progenitor cells, 402
relevance to treatment of bipolar disorder and, 403
weight gain with, 52
- Valproate/divalproex sodium, dosage and serum-level monitoring of, 305-306
in acute mania, 302-304
in bipolar depression, 304-305
maintenance efficacy of, 305
pharmacologic profile of, 303
tolerability of, 306
- Venlafaxine, in elderly patients, 828
- Ventricles, in structural magnetic resonance imaging, in bipolar disorder, 448-449
- Verbal fluency, in schizophrenia, 619
- Verbal learning and memory, in schizophrenia, 618-619
- Very-low calorie diet, in Health Management Resources weight loss program, 180-181
in medically monitored weight loss programs, 184-185
- Very-low calorie diets, adverse effects of, 179-180
in obesity, with behavioral treatment, 158
- Very-low fat diet(s), efficacy of, 127
Pritikin, Ornish, 126-127
vegetarian, 127
- Video-EEG monitoring, 646
- Vigilance, impaired, in schizophrenia, 616
- Violence, causes and manifestations of, 702
correlates and predictors of, 703, 705
defined, 702
factors associated with, 703-704
history as predictor of, 705
in acute care settings, 701-702
prevention of, 702-705
management of, 706-710
de-escalation, 707-708
environmental manipulation, 707
pharmacologic interventions, 708-710
restraints and seclusion, 708
organic causes of, 703-704
pharmacologic management of, choice of agent, 708
least restrictive, 710
patient participation in, 708-709

- rapid tranquilization in, 709
 - psychiatric and nonpsychiatric
 - disorders associated with, 703, 706
 - safety do's and don'ts, 702-703, 707
 - Visuospatial processing function,
 - assessment of, 525, 528
 - parameters of, 525, 527
 - Visuospatial syndromes, 528
 - Visuospatial vs. verbal functioning, in bipolar disorder, 432-433
- W**
-
- Waist circumference, in examination of
 - obese patient, 95
 - obesity and comorbidities, 112-113
 - Weight control, commercial and self-help programs for, **171-192**
 - lifestyle modification in, 172
 - medically supervised proprietary programs, Health Management Resources, 174, 176, 180-181, 184-185, 189
 - Medifast, 174, 176, 183-184
 - OPTIFAST, 174, 176, 182-183, 189
 - summary of, 184-185
 - very-low calorie diets in, 179-180
 - nonmedical commercial programs for, 173-179
 - Internet-based, 185-186
 - Jenny Craig, 174-176, 178
 - LA Weight Loss, 174, 178-179
 - summary of, 179
 - Weight Watchers, 173-175
 - Weight gain, depression and, 45-46
 - education and, 6
 - income level and, 7
 - in overweight and obese individuals, 6-7
 - medications associated with, 94
 - with atypical antipsychotics, 47-48, 392-393
 - Weight loss, body image and,
 - improvement of, 80-81
 - in depression, 46

- Weight reduction, in body image therapy, 72-73
- Weight Watchers, components of, 173-175
 - costs of, 175-176
 - outcomes of, 175
- White matter. See also *Cerebral white matter*.
 - diffusion tensor imaging MRI examination of, 555-556
 - in memory, 590
- White matter dementia, 697
- White matter disease, memory deficits in, 592
- White matter hyperintensities, in structural magnetic resonance imaging, in bipolar disorder, 444
- Wilson's disease, behavioral and personality changes in, 283
 - diagnosis of, 283
 - heritability of, 282
 - neurological manifestations of, 283
 - presentation of, 283
 - suicide risk with, 283
- Wisconsin Card Sorting Test, in schizophrenia, 620
 - of executive control, 570
- Working memory, 522, 524
 - as actor-centered construct, 576
 - assessment of, 576-577
 - domain specificity in, 568
 - frontal lobes in, 576
 - in schizophrenia, 616-617
 - process specificity in, 568-569
 - visual, 616-617

Z

- Ziprasidone, in bipolar disorder, in children and adolescents, 393
 - in older patients, 972
- Zonisamide, acute efficacy of, 316
 - dosing of, 316
 - in bipolar depression, 356
 - in weight loss, 204
 - tolerability of, 317